Autolus TherapeuticsAUTL
Recorded

Autolus Therapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration25 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Roger SongAnalyst

All right. Welcome, everyone, to 2026 Jefferies Global Healthcare Conference. My name is Roger Song, senior analyst covers biotech in the U.S. It is my pleasure to have the fireside chat with our company, Autolus, and CEO Chris Itin. Chris will do a quick overview of the company for a couple minutes, and then sit down with me for the rest of the fireside chat. Thank you, Chris. Thank you.

Christian ItinCEO

Well, welcome everybody. Thanks for joining. I know this is going to be hard right after lunch, so I want to make sure the energy level's going to be good in the room, and we're going to keep it there. Thanks a lot for joining. I'll lead you through a few introductory slides on where we are and what we do at Autolus, and then we're going to do the Q&A with Roger. As usual, forward-looking statements, please have a look at our SEC filings for that in more detail. The focus of the company is clearly on our lead asset, which is AUCATZYL or obe-cel. It's a CAR T therapy that is approved for patients with relapsed refractory acute leukemia. We're on the market since the beginning of 2025 in the U.S., and since the beginning of 2026 in the U.K.

Christian ItinCEO

We had a good first year with about $74 million in revenue, and now in the second year for the first three months, or three quarters, we're reaching $113 million in revenue. We just had the Q3 numbers, which came in at $41 million. We did actually increase our guidance. We had initially guided at the beginning of the year between $120 million and $135 million. With the Q2 numbers, we increased the guidance to $140 million to $150 million, and we're now coming in at $150 million or somewhat above it. We have a very good trajectory that we're seeing. It's really built on very strong execution with the product. We're currently in about 90 centers in the U.S., and at about 20 centers in the U.K. The product has been very well accepted in the market.

Christian ItinCEO

We've seen that with the real-world experience being actually presented by the ROCCA Consortium, which is a consortium in the U.S. to collect real-world data. They collected actually data from about two-thirds of our patients in the first year of launch, and that data was quite remarkable because it showed a remarkable safety profile, no high-grade cytokine release syndrome, only 3% of the patients that had some higher-grade neurological toxicity, which was transient, and overall a remarkable level of clinical activity in the range of 90% plus. What we're seeing with that is now actually that experience has really propelled this year, and when the data got presented at ASTCT in February, we could see the impact. We could see the number of physicians that were actually prescribing the product increase, and actually continue to increase steadily, and we could see a very significant step up.

Christian ItinCEO

We're going to expect overall about 100% increase year-over-year for our second year of launch. Very nice dynamic, very well corroborated by the real-world experience, and this is a disease setting where it's really the physicians that are driving the uptake. It's the experience, the confidence the physicians have, and this is why this peer-to-peer conversation and communication is such an important aspect of it. Now, moving just in a quick words on where we are, obviously it's important that we're driving our top line, and I just talked about that. But the other aspect is also that we need to make sure that with this individualized manufacturing that we're running for a CAR T therapy, you also have to make sure that indeed you can create margins over time.

Christian ItinCEO

In part, margins are driven by volume, because obviously there's infrastructure cost, you're going to break down on a larger number of products, but there is also very significant improvements on efficiency. To give you a sense for that as we go through the course of this year, we're going to manufacture twice as much product as we manufactured last year with less operators and less people in our manufacturing environment. So, a substantial step up in efficiency that we are able to realize. This has been an ongoing process, and we keep pushing that. For Q3, we're at 57% gross margin. Year to date, we're at 44%. This is a remarkable outcome in a second year of launch with a personalized therapy. This is critical. What we're driving is we're really driving to increase this margin, and we expect to be in the 2028 timeframe in the 65%-70% range, and we also expect that the ALL business will be cash flow positive in the 2028 timeframe.

Christian ItinCEO

We already talked about commercial expansion. I mentioned we already have set out a goal of 80 centers. We already hit at 90, and we'll keep going. With that, obviously what we're really looking to do is take this opportunity we have, this foothold that we now have in acute leukemia in the relapsed refractory setting, and expand the utility of the product. There are two dimensions we're going to take. One is into pediatric patients. There's two peaks where you have a lot of patients that are showing up with acute leukemia.

Christian ItinCEO

It's with children, and it's with the older adults. This is kind of two peaks that you see. This gives us the opportunity to get into this younger population. We're currently conducting a pivotal study. We expect that study to be fully enrolled by the end of this year or very early next year, and data at ASH next year, and also with an sBLA filing ready at that point in time as well. That sets us up to go into the dimension across all age groups. The second dimension is moving into the frontline setting. What we're currently supporting are frontline studies by investigators. This includes MD Anderson, Memorial Sloan Kettering, Stanford, City of Hope in the U.S. What they are trying to do is really change the paradigm on how we treat patients in the frontline setting.

Christian ItinCEO

Today, when you look at a frontline treatment, it's a sequence of therapy cycles that take 18-36 months. It starts with high-dose chemotherapy induction cycles. Eventually, there is a T-cell engager, blinatumomab, that's being administered. There's inotuzumab in the mix, and there is maintenance chemotherapy. Overall, 18-36 months. What we've learned with the ECOG-ACRIN E1910 study, which was the big study that tried to establish blinatumomab in the frontline setting, is that as we're looking at the elderly patient population that were treading water, the intensification of the treatment for these patients was actually driving up treatment mortality, treatment-related mortality, to a point where net survival no longer improved. That is important. That was a watershed moment in this disease setting.

Christian ItinCEO

There is a clear drive now to actually collapse the frontline treatment, reduce the toxicity, and get to a definitive consolidation as early as possible. So what we're currently doing in those studies is treating patients with two cycles of induction chemotherapy followed by definitive consolidation using obe-cel or AUCATZYL. That will collapse that frontline treatment from this 18-36 months down to four to six months. It's a huge change. This is what's currently in the works. We're expecting first data from MD Anderson at the end of next year, and then follow-up data afterwards. We're in conversation with cooperative groups and the NCI for potentially a randomized controlled label-enabling study as well as we go forward.

Christian ItinCEO

The upside of that is that we believe that this will allow us to go from, in the U.S., about a $500 million peak sale potential in the relapse refractory adult setting, to an opportunity that will actually allow us to cross a $1 billion in peak sale opportunity across the entire age range, as well as across all lines of therapy. So this is important because this creates a very strong foundation for the business. It also creates an approach that has a very high level of clinical activity, a good safety profile, and with that, has the opportunity to become standard of care across the indication. That's what we're aiming for. So that's the foundation for the business. Now, with that, just a few additional thoughts, and this is kind of where to go next.

Christian ItinCEO

You've seen a lot of information, a lot of data over the last two or three, four years, looking at very deep depletion of B cells in autoimmune disease. There are two areas that we're currently active in. One is in progressive MS, where the idea is that there is a proportion of B cells that are sitting in behind the blood-brain barrier in the central nervous system, not touchable by normal therapeutics because they cannot cross the blood-brain barrier. The cell therapy can do that. We know that because many of our patients in leukemia have leukemia in the central nervous system, and we can demonstrate that indeed these patients can be cleared and that the clearance actually is safe. Okay? With that knowledge, what we're doing now is we're moving into these patients and to test a hypothesis whether indeed those cells behind the blood-brain barrier are the drivers of the progression that we see in these patients.

Christian ItinCEO

The scoring you have to look at is called EDSS. It's a composite score, including patient-reported outcomes. In order to actually know that there is stability in the data, you have to make sure that you have adequate level of observation time. You need about 12 to 24 months to actually understand that the data is robust. We expect to have our first data come out in October next year, and that will give us about 12 patients with more than 12 months of follow-up, and also an additional 12 with about six to 12 months of follow-up as well.

Christian ItinCEO

That gives us, I think, a very good, I think, first data set in progressive MS. We're also active in addition indications. I already mentioned what we expect to see. We're also active on the lupus nephritis side. We have ongoing the pivotal study called LUMINA, and we've just presented data at the ACR conference showing that indeed we can do long-term benefit in these patients and long-term immune reset, in SLE patients with refractory disease. This is kind of where we are, and I think with that, I'm going to stop here, and we're going to go in Q&A mode.

Roger SongAnalyst

Excellent. Thanks, Chris. Yeah, Wilson. All right. I think obe-cel is definitely off a very good launch trajectory, and then this year you surprised us maybe a couple times with a higher, positive surprise. That's good. Maybe just zooming for U.S. versus ex-U.S., focus on the U.S. for sure, now you have, on the size of 80, maybe moving towards 90 kind of centers. What will be driving the next wave of the growth? More center, more referral, or more conversion to the treatment?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day